Profile

Allison Brashear, M.D.Wake Forest School of Medicine

Doctor Rating

No Rating Available
Why No Ratings?

Allison Brashear, M.D.

Chair,
Interim Chair,
Professor,



Clinical Interests

Movement Disorders, Neuromuscular Diseases, Botulinum Toxin

Contact Information

Request An Appointment

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-716-4101
Department: 336-716-4101

Insurance Accepted »

Media Medical Expert »

Related Links

Education & Training

  • B.A., Depauw University , 1983
  • M.D., Indiana University School of Medicine , 1987
  • Internship, Medicine, Indiana Univ Med Ctr & Hosps, 1988
  • Residency, Neurology, Indiana Univ Med Ctr & Hosps, 1991

Board Certifications

  • American Board of Psychiatry & Neurology, Neurology, Psychiatry & Neurology - Neurology

Memberships

  • American Academy Of Neurology

NPI Number

  • 1881673713
Allison Brashear, M.D.

Doctor Rating

No Rating Available
Why No Ratings?

Allison Brashear, M.D.

Chair, Neurology
Interim Chair, Psychiatry and Behavioral Medicine
Professor, Neurology
Hypertension and Vascular Research Center
Office of Women in Medicine and Science
Gerontology and Geriatric Medicine

Research Interests

drugs/therapeutic agents pharm, epidemiology, health services, research/outc, mental disorders/psychiatry/ps, neurosciences/behavior

Contact Information

Request An Appointment

Academic: 336-716-3545 | Department: 336-716-4101

Media Medical Expert »

Related Links

Recent Publications

Brashear A, Ozelius LJ, Sweadner KJ. ATP1A3 mutations: what is the phenotype? [editorial]. Neurology. 2014;82(6):468-469.

Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A. Cognitive impairment in rapid-onset dystonia-parkinsonism. Mov Disord. 2014;29(Suppl 3):344-350.

Heinzen EL, Arzimanoglou A, Brashear A, Clapcote SJ, Gurrieri F, Goldstein DB, Johannesson SH, Mikati MA, Neville B, Nicole S, Ozelius LJ, Poulsen H, Schyns T, Sweadner KJ, van den Maagdenberg A, Vilsen B. Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol. 2014;13(5):503-514.

Saunders-Pullman R, Fuchs T, San Luciano M, Raymond D, Brashear A, Ortega R, Deik A, Ozelius LJ, Bressman SB. Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Mov Disord. 2014;29(6):812-818.

Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B. Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. Acta Neuropathol. 2014;128(1):81-98.

Tate J, Brashear A, Whitlow C, Snively B, Ozelius L, Sweadner K, Stacy M, Haq I. Rapid-onset dystonia-Parkinsonism presenting as tremor-dominant Parkinson's disease (PO4.161) [abstract]. Neurology. 2013;80(1 Meeting Abstracts):P04.

Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur J Neurol. 2013;20(5):773-780.

Brashear A. Commentary. Mov Disord. 2013;28(14):1939.

Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin) in cervical dystonia. J Neural Transm. 2013;120(12):1699-1707.

Brashear A, Bushong L. Coding for the use of botulinum toxin for movement disorders. Continuum (Minneapolis, Minn.). 2013;19(5):1406-1415.

Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH, Brashear A. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin) injections in blepharospasm. J Neural Transm. 2013;120(9):1345-1353.

Brashear A. Treatment of cervical dystonia. Expert Opin Orphan Drugs. 2013;1(8):599-606.

Brashear A, Cook J, Amponsah A, Hill D, Snively B, Light L, Suerken C, McCall WV, Boggs N, Stacy M, Ozelius L, Sweadner K. Psychiatric and neurocognitive morbidity in rapid-onset dystonia Parkinsonism [abstract]. Neurology. 2012;78(Suppl 1):P01.225.


Ghetti B, Brashear A, Hagen M, Sweadner K. Rapid onset dystonia-Parkinsonism associated with the I758S ATP1A3 mutation: a neuropathologic study of two affected siblings [abstract]. J Neuropathol Exp Neurol. 2012;71(6):592-593.

Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. Parkinsonism Relat Disord. 2012;18(6):737-741.

Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, Elovic EP. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM R. 2012;4(1):4-10.

Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S. Patient registry of outcomes in spasticity care. Am J Phys Med Rehabil. 2012;91(9):729-746.

Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology. 2012;79(11):1168-1173.

Charles D, Brashear A, Hauser RA, Li H-I, Boo L-M, Brin MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35(5):208-214.

Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol. 2012;54(11):1065-1067.

Brashear A, Elovic E, eds. In: Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: .

Brashear A, Elovic E. Why is spasticity important? In: Brashear A, Elovic E, eds. Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: 3-4.

Brashear A. Botulinum toxin in the treatment of upper limb spasticity In: Brashear A, Elovic E, eds. Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: 131-140.


Brashear A, Hill DF, Boggs N, Ozelius L, Sweadner KJ, Light L, Stacy M, Snively BM, McCall WV. Psychosis: part of the rapid-onset dystonia-Parkinsonism (RDP) phenotype? [abstract]. Neurology. 2011;76(9 Suppl 4):A640.

Evidente VGH, Fernandez HH, LeDoux MS, Brashear A, Marx MW, Grafe SK, Comella CL. Flexible dosing with incobotulinumtoxin-A (Xeomin); botulinum neurotoxin type-A, free from accessory proteins) in cervical dystonia [abstract]. Eur J Neurol. 2011;18(Suppl 2):511.

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316-323.

Brashear A, Hill D, Snively BM, Sweadner KJ, Ozelius L. De novo and recurrent mutations in ATP1A3 are common in rapid-onset dystonia-Parkinsonism [abstract]. Neurology. 2010;74(9 Suppl 2):A204.

Yablon SA, Simpson D, Gracies JM, Barbano R, Brashear A. Tizanidine improves geriatric depression scale scores in stroke and brain injury survivors with spastic hemiparesis: post-hoc analysis from a randomized, double-blind, placebo-controlled trial [abstract]. Neurology. 2010;74(9 Suppl 2):A409-A410.

Brashear A, Hill DF, Snively B, Sweadner KJ, Ozelius L. Now triggers in rapid-onset dystonia-Parkinsonism (RDP) [abstract]. Neurology. 2010;74(9 Suppl 2):A205.

Brashear A. Botulinum toxin type A: exploring new indications. Drugs Today (Barc). 2010;46(9):671-682.

Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80(4):380-385.

Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009;11(3):153-161.

Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009;3():1-7.

Sacino A, Hampton TG, Lingrel JB, Brashear A, Sweadner KJ. Rapid onset dystonia-parkinsonism: symptoms in a mouse deficient in Na,K-ATPase alpha3 [abstract]. Mov Disord. 2009;24(Suppl 1):S112-S113.

Gracies J-M, Yablon S, Raghavan P, Barbano R, Brashear A, Simpson D. Relationship between active function and tone in a placebo-controlled study of botulinum neurotoxin vs tizanidine in upper limb spasticity [abstract]. Arch Phys Med Rehabil. 2009;90(10):e5-e6.

Barbano RL, Ozelius L, Hill DF, Brashear A. Variable phenotypic expression of rapid onset dystonia parkinsonism in a newly discovered Italian family with a T613M mutation in the ATP1A3 gene [abstract]. In: Abstracts of the 61st Annual Meeting of the American Academy of Neurology; 2009 April 25 - May 2; Seattle (WA). 2009;():IN2-1.003.

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699-1706.


Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008;14(5):289-298.

Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJM, Gollamudi S, Green A, Guimaraes J, Haake B, Klein C, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain. 2007;130(Pt 3):828-835.

Yablon SA, Brashear A, Gordon MF, Elovic DP, Turkel CC, Daggett S, Liu J, Brin MF. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007;29(4):683-690.

Brashear A, Farmer D, Wood F, Bressman SB, Dobyns WB, Ozelius LO. ATP1A3 mutations in rapid-onset dystonia Parkinsonism: is there more to the story? [abstract]. Ann Neurol. 2006;60(Suppl 10):S11.

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67(12):2233-2235.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Neurology

Clinical Interests

Movement Disorders, Neuromuscular Diseases, Botulinum Toxin
Allison Brashear, M.D.
CP concern for questions/worries
3.9
CP efforts to include in decisions
4
CP explanations of prob/condition
4.1
CP spoke using clear language
4.3
Friendliness/courtesy of CP
4.4
Likelihood of recommending CP
4.3
Patients' confidence in CP
4.2
Time CP spent with patient
4.3
Wait time at clinic
4.3



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

7/28/2014

*Dr. Brashear showed great concern for my issues & I feel that she expressed a desire to help me improve.

3/6/2014

Caring and concern!

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give

Spotlight

New Hope for the Treatment of Upper Limb Spasticity

Learn more about the symptoms of upper limb spasticity and new treatment options to help patients live better and more active lives.

USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.